bendamustine hydrochloride has been researched along with Neutropenia in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (8.00) | 29.6817 |
| 2010's | 18 (72.00) | 24.3611 |
| 2020's | 4 (16.00) | 2.80 |
| Authors | Studies |
|---|---|
| Butera, J; Egan, P; MacKinnon, K; Margolis, J; McMahon, J; Ollila, T; Olszewski, AJ; Reagan, J; Rosati, V; Thomas, A; Yakirevich, I | 1 |
| Cen, H; Ding, K; Gao, Y; Huang, H; Lin, J; Liu, Y; Lv, F; Ma, L; Song, B; Tang, X; Wang, S; Wang, Y; Wu, D; Wu, J; Xiang, Y; Xu, W; Yang, Y; Ye, X; Yu, H; Zhang, F; Zhang, Q; Zhao, Y; Zhou, J | 1 |
| Bramowicz-Jarosz, B; Długosz-Danecka, M; Graboś-Michalak, J; Hus, I; Kopacz, A; Krochmalczyk, D; Malenda, A; Piotrowska, M; Potoczek, S; Raźny, M; Seweryn, M; Soroka-Wojtaszko, M; Szymczyk, A; Wąsik-Szczepanek, E; Wichary, R; Wołowiec, D; Zawirska, D | 1 |
| Földeák, D; Gopcsa, L; Illés, Á; Miltényi, Z; Pinczés, LI; Piukovics, K; Szabó, R; Szomor, Á | 1 |
| Bosch, F; Böttcher, S; Foà, R; Ilhan, O; Kisro, J; Leblond, V; Mahé, B; Mikuskova, E; Osmanov, D; Perretti, T; Reda, G; Robinson, S; Stilgenbauer, S; Tausch, E; Trask, P; Turgut, M; Van Hoef, M; Wójtowicz, M | 1 |
| Bouredji, K; Chamorey, E; Deletie, E; Gastaud, L; Peyrade, F; Quinsat, D; Re, D; Schiappa, R; Thyss, A; Verriere, B | 1 |
| Assouline, S; Boyer, M; Cartron, G; D'Rozario, J; De la Serna, J; Eichhorst, B; Gerecitano, J; Hillmen, P; Humerickhouse, R; Humphrey, K; Jaeger, U; Kater, AP; Kipps, TJ; Li, Y; Mobasher, M; Montillo, M; Owen, C; Punnoose, EA; Robak, T; Seymour, JF | 1 |
| Chinen, Y; Fuchida, SI; Horiike, S; Iwai, T; Kaneko, H; Kawata, E; Kiyota, M; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Nakao, M; Nishigaki, H; Ohshiro, M; Shimazaki, C; Shimura, K; Shimura, Y; Sugitani, M; Takimoto-Shimomura, T; Taniwaki, M; Uchiyama, H; Uoshima, N; Yoshida, M | 1 |
| Do, YR; Hong, JY; Hyun, SY; Jo, JC; Kim, JA; Kim, MK; Kim, WS; Koh, YI; Lee, SS; Lee, WS; Oh, YH; Park, BB; Suh, C; Won, JH; Yang, DH | 1 |
| Ambrosetti, A; Castelli, M; Cortelazzo, S; Fanin, R; Isola, M; Mian, M; Nichele, I; Paolini, R; Pizzolo, G; Puglisi, S; Rodeghiero, F; Sancetta, R; Semenzato, G; Sissa, C; Trentin, L; Visco, C; Vivaldi, P; Volpetti, S; Zaja, F | 1 |
| Butrym, A; Dmoszynska, A; Dzietczenia, J; Gorska-Kosicka, M; Grzegorz, M; Hus, I; Jawniak, D; Jedrzejczak, WW; Krawczyk-Kulis, M; Kyrcz-Krzemien, S; Lech-Maranda, E; Poplawska, L; Walewski, J; Warzocha, K; Waszczuk-Gajda, A; Wrobel, T | 1 |
| Cheson, BD; Gehan, E; Ramzi, P; Ujjani, C; Wang, H; Wang, Y | 1 |
| Cheson, BD; Crawford, J | 1 |
| Aisa, Y; Chen, K; Hagihara, M; Ishida, A; Masuda, Y; Matsumoto, K; Miyakawa, Y; Nakajima, H; Nakaya, A; Nakazato, T; Okamoto, S; Shimizu, T; Takayama, N; Tsukada, Y; Ueno, H; Watanabe, K; Yamada, Y; Yano, T; Yokoyama, K | 1 |
| Avigdor, A; Balasubramanian, S; Bartlett, NL; Chanan-Khan, A; Cramer, P; Demirkan, F; Dilhuydy, MS; Fraser, G; Goy, A; Grosicki, S; Hallek, M; Howes, A; Janssens, A; Karlsson, C; Loscertales, J; Mahler, M; Mato, A; Mayer, J; Panagiotidis, P; Pavlovsky, MA; Phelps, C; Pristupa, A; Pylypenko, H; Rule, S; Salman, M; Samoilova, O; Silva, RS; Sun, S; Villa, D | 1 |
| Awan, FT; Byrd, JC; Eisenfeld, AJ; Garcia-Marco, JA; Hallek, M; Hebart, H; Hellmann, A; Hill, BT; Jaeger, U; Kloczko, J; Lech-Maranda, E; Loscertales, J; Mato, A; Pagel, JM; Robak, T; Stromatt, SC | 1 |
| Aldaoud, A; Becker, M; Del Giudice, I; Fricke, HJ; Gercheva, L; Goranov, S; Herbrecht, R; Huguet, F; Juliusson, G; Klein, P; Knauf, WU; Liberati, A; Lissichkov, T; Loscertales, J; Merkle, K; Montillo, M; Postner, G; Tremmel, L | 1 |
| D'Andrea, D; Darwish, M; Kahl, B; Melhem, M; Owen, JS; Passarell, JA | 1 |
| Ando, K; Kasai, M; Matsumoto, Y; Ogawa, Y; Ogura, M; Ohmachi, K; Shimizu, D; Taniwaki, M; Tobinai, K; Uchida, T; Watanabe, T; Yokoyama, H | 1 |
| Ando, K; Choi, I; Ishizawa, K; Itoh, K; Kubota, N; Nagai, H; Ogura, M; Ohmachi, K; Terui, Y; Tobinai, K; Uchida, T; Uike, N; Uoshima, N; Usuki, K; Watanabe, T; Yamamoto, J | 1 |
| Al-Batran, SE; Atmaca, A; Fauth, F; Jäger, E; Neumann, A; Pauligk, C; Weidmann, E | 1 |
| Alizadeh, AA; Hosein, PJ; Lossos, IS; Maeda, LS; Warsch, S | 1 |
| D'Amore, ES; Finotto, S; Menin, A; Paolini, R; Pizzolo, G; Rodeghiero, F; Semenzato, G; Visco, C; Zaja, F; Zambello, R; Zanotti, R | 1 |
| Grünwald, V; Hartmann, JT; Horger, M; Huober, J; Käfer, G; Kanz, L; Mayer, F; Meisinger, I; Pintoffl, J; Schleicher, J | 1 |
| Güttner, J; Härtl, A; Hoffmann, H; Horn, U | 1 |
16 trial(s) available for bendamustine hydrochloride and Neutropenia
| Article | Year |
|---|---|
Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bendamustine Hydrochloride; Humans; Ileus; Liposomes; Lymphoma, B-Cell; Lymphopenia; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rituximab; Vincristine | 2022 |
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Pharmacological; Chlorambucil; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Non-Randomized Controlled Trials as Topic; Progression-Free Survival; Recurrence; Safety; Thrombocytopenia; Treatment Outcome; Vidarabine | 2021 |
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Recurrence; Rituximab; Sulfonamides; Tumor Lysis Syndrome; Young Adult | 2018 |
Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytomegalovirus Infections; Dexamethasone; Drug Administration Schedule; Female; Humans; Leukopenia; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutropenia; Rituximab; Salvage Therapy; Young Adult | 2019 |
A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial).
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carboplatin; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Progression-Free Survival; Salvage Therapy; Thrombocytopenia; Young Adult | 2019 |
Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Humans; Infections; Infusions, Intraventricular; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Retreatment; Treatment Outcome | 2015 |
A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Thalidomide | 2015 |
A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Drug Administration Schedule; Female; Humans; Leukopenia; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Rituximab; Treatment Outcome; Young Adult | 2015 |
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bendamustine Hydrochloride; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Hemorrhage; Humans; Intention to Treat Analysis; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nausea; Neutropenia; Piperidines; Pyrazoles; Pyrimidines; Retreatment; Rituximab; Thrombocytopenia | 2016 |
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Drug Administration Schedule; Female; Fever; Humans; Immunoglobulin G; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Recombinant Fusion Proteins; Recurrence; Remission Induction; Salvage Therapy | 2017 |
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Chlorambucil; Disease-Free Survival; Female; Fever; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nausea; Neutropenia; Nitrogen Mustard Compounds; Thrombocytopenia; Time Factors; Treatment Outcome | 2009 |
Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Lung Diseases, Interstitial; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Metabolic Clearance Rate; Middle Aged; Molecular Structure; Neutropenia; Nitrogen Mustard Compounds; Recurrence; Treatment Outcome | 2010 |
Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Bendamustine Hydrochloride; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Nitrogen Mustard Compounds; Pneumonia; Recurrence; Treatment Outcome; Vomiting | 2010 |
Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell; Male; Neoplasm Staging; Neutropenia; Nitrogen Mustard Compounds; Rituximab | 2011 |
Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Leukopenia; Lymphoma, Mantle-Cell; Male; Middle Aged; Nausea; Neutropenia; Nitrogen Mustard Compounds; Positron-Emission Tomography; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Outcome; Vomiting | 2013 |
Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001).
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Agents; Bendamustine Hydrochloride; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fever; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Sarcoma; Treatment Outcome | 2007 |
9 other study(ies) available for bendamustine hydrochloride and Neutropenia
| Article | Year |
|---|---|
Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chronic Disease; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Rituximab; Treatment Outcome; Young Adult | 2023 |
Safety and Efficacy of Bendamustine Monotherapy in the First-Line Treatment of Patients with Chronic Lymphocytic Leukemia: Polish Lymphoma Research Group Real-Life Analysis.
Topics: Aged; Aged, 80 and over; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Retrospective Studies; Survival Rate; Thrombocytopenia; Treatment Outcome | 2019 |
Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Combined Modality Therapy; Drug Evaluation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Neutropenia; Peripheral Nervous System Diseases; Positron-Emission Tomography; Progression-Free Survival; Retrospective Studies; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Young Adult | 2020 |
Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Bendamustine Hydrochloride; Female; Humans; Lymphoma; Male; Middle Aged; Neutropenia; Rituximab | 2018 |
Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Neutropenia; Nitrogen Mustard Compounds; Prognosis; Reproducibility of Results; Retrospective Studies; Rituximab; Survival Analysis | 2013 |
Bendamustine as monotherapy and in combination regimens for the treatment of chronic lymphocytic leukemia and non-hodgkin lymphoma: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Retrospective Studies; Rituximab; Thrombocytopenia | 2013 |
Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Bendamustine Hydrochloride; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Time Factors; Treatment Outcome | 2010 |
A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Humans; Infections; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2012 |
Toxicity of the alkylating agent bendamustin.
Topics: Alkylating Agents; Animals; Atrophy; Bendamustine Hydrochloride; Body Weight; Chlorambucil; Digestive System; Kidney Diseases; Lethal Dose 50; Lymphoid Tissue; Male; Mice; Neutropenia; Nitrogen Mustard Compounds; Rats; Testis | 1985 |